LY2334737 10 mg | 99.40%
TargetMol
LY2334737 is an orally available prodrug of gemcitabine with antineoplastic activity.
More Information Supplier PageLY2334737
Search Results
Selamectin 5 mg | Purity Not Available
TargetMol
Selamectin is a macrocyclic lactone derivative of ivermectin, an anthelmintic that potentiates glutamate- and GABA-gated chloride channel opening in nematodes. In an H. contortus larval development assay, selamectin (0.1 μg/ml) shows the effect of growth inhibition.
More Information Supplier PageSelamectin
Selamectin 50 mg | Purity Not Available
TargetMol
Selamectin is a macrocyclic lactone derivative of ivermectin, an anthelmintic that potentiates glutamate- and GABA-gated chloride channel opening in nematodes. In an H. contortus larval development assay, selamectin (0.1 μg/ml) shows the effect of growth inhibition.
More Information Supplier PageSelamectin
Selamectin 25 mg | Purity Not Available
TargetMol
Selamectin is a macrocyclic lactone derivative of ivermectin, an anthelmintic that potentiates glutamate- and GABA-gated chloride channel opening in nematodes. In an H. contortus larval development assay, selamectin (0.1 μg/ml) shows the effect of growth inhibition.
More Information Supplier PageSelamectin
CAY10602 10 mg | 98.87%
TargetMol
CAY10602 is a SIRT1 activator. CAY10602 was derived from high throughput screening for compounds that increase SIRT1-mediated deacetylation of a SIRT1-specific substrate. Functional assays show that CAY10602 dose-dependently suppresses the NF-κB-dependent induction of TNF-α by lipopolysaccharide in THP-1 cells, with approximately 75% inhibition achieved at 60 μM, without cytotoxicity.
More Information Supplier PageCAY10602
CAY10602 25 mg | 98.87%
TargetMol
CAY10602 is a SIRT1 activator. CAY10602 was derived from high throughput screening for compounds that increase SIRT1-mediated deacetylation of a SIRT1-specific substrate. Functional assays show that CAY10602 dose-dependently suppresses the NF-κB-dependent induction of TNF-α by lipopolysaccharide in THP-1 cells, with approximately 75% inhibition achieved at 60 μM, without cytotoxicity.
More Information Supplier PageCAY10602
GSK-872 100 mg | 99.30%
TargetMol
GSK-872 (GSK2399872A) is an effective and specific RIP3 kinase inhibitor. It binds RIP3 kinase domain with high affinity (IC50: 1.8 nM) and inhibits kinase activity (IC50: 1.3 nM).
More Information Supplier PageGSK-872
Repotrectinib 5 mg | 99.86%
TargetMol
Repotrectinib (TPX-0005) is a potent ALK/ROS1/TRK inhibitor, with IC50 of 1.01 nM, 5.3 nM, 1.08 nM and 1.26 nM for WT ALK, SRC, ALK L1196M and ALK G1202R, respectively.
More Information Supplier PageRepotrectinib
Repotrectinib 50 mg | 99.86%
TargetMol
Repotrectinib (TPX-0005) is a potent ALK/ROS1/TRK inhibitor, with IC50 of 1.01 nM, 5.3 nM, 1.08 nM and 1.26 nM for WT ALK, SRC, ALK L1196M and ALK G1202R, respectively.
More Information Supplier PageRepotrectinib
Repotrectinib 25 mg | 99.86%
TargetMol
Repotrectinib (TPX-0005) is a potent ALK/ROS1/TRK inhibitor, with IC50 of 1.01 nM, 5.3 nM, 1.08 nM and 1.26 nM for WT ALK, SRC, ALK L1196M and ALK G1202R, respectively.
More Information Supplier PageRepotrectinib